Issue 46 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

9

No.

46

December 02, 1983Dec 02, 1983

Free

DOWNLOAD THE PDF

Full Funding Of Indirect Costs, Other Mandates By Congress Chew Up Most Of NCI’s Extra Money

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

Five Year Survival Up To 48 Percent; DeVita Has “No Doubt” It Is Really Over 50 Percent Now

Cooperative Group Chairman Unhappy Over Exclusion From Funding at Recommended Levels

Workshop Calls For Improved Surgical Oncology Training Programs

Recent Issues

Volume 50 | Issue 44 - November 22, 2024

Volume 50 | Issue 43 - November 15, 2024

Volume 50 | Issue 42 - November 08, 2024

Volume 50 | Issue 41 - November 01, 2024

Volume 50 | Issue 40 - October 25, 2024

Volume 50 | Issue 39 - October 18, 2024